Aclaris Therapeutics Approves 2025 Equity Incentive Plan

Aclaris Therapeutics ( (ACRS) ) just unveiled an announcement.

On June 5, 2025, Aclaris Therapeutics‘ stockholders approved the 2025 Equity Incentive Plan, succeeding the 2015 plan, during their annual meeting. Additionally, they approved an amendment to increase the authorized common stock shares from 200 million to 400 million, reflecting strategic growth intentions. The meeting also resulted in the election of three board directors, approval of executive compensation, and ratification of PricewaterhouseCoopers LLP as the accounting firm for 2025.

The most recent analyst rating on (ACRS) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Aclaris Therapeutics stock, see the ACRS Stock Forecast page.

Spark’s Take on ACRS Stock

According to Spark, TipRanks’ AI Analyst, ACRS is a Neutral.

Aclaris Therapeutics is currently facing significant challenges, with a primary focus on its financial performance. The company’s lack of profitability and reliance on external financing are major concerns. The technical analysis further underscores negative momentum, although oversold indicators might suggest a potential short-term rebound. Valuation is unattractive due to negative earnings, and no significant earnings call data or corporate events are available to offset these issues.

To see Spark’s full report on ACRS stock, click here.

More about Aclaris Therapeutics

Aclaris Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on developing therapies for dermatological and immunological conditions. The company primarily offers innovative treatments targeting specific disease pathways, aiming to address unmet medical needs in these markets.

Average Trading Volume: 930,882

Technical Sentiment Signal: Sell

Current Market Cap: $159.2M

See more data about ACRS stock on TipRanks’ Stock Analysis page.